On November 7, 2013, the sixth Friends-Brookings conference was held in Washington, DC, with generous support from the American Society for Clinical Oncology and Susan G. Komen for the Cure. This year's conference, attended by hundreds of leaders in their fields, featured three sessions that proposed innovative approaches to current challenges in drug development:
Panel Two: Lung Cancer Master Protocol Activation Announcement
Panel Three: Optimizing Dosing of Oncology Drugs
Immunotherapies hold the potential for long-term antitumor activity; however, the response to immunotherapies is often delayed. The pre-conference white paper that was put forth sought to identify new tools for measuring the activity of immunotherapies, and proposed several endpoints that could account for the potential of delayed treatment effect.
L-R: Amy McKee, Steven Rosenberg, Tai-Tsang Chen, Axel Hoos, Ramy Ibrahim, Mark Gorman
L-R: Mary Redman, Jeff Abrams, Vince Miller, Ann Ashby, Vali Papadimitrakopoulou, David Gandara, Janet Woodcock, Roy Herbst, Jeff Allen
|L-R: Richard Pazdur, Oliver Rosen, Lori Minasian, Daniel Auclair, Atiqur Rahman, Richard Schilsky|